31.83

1.82% 0.57

After Hours: 31.83

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $31.83, with a volume of 378.60K. It is up +1.82% in the last 24 hours and up +13.84% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$31.26

Open:

$31.5

24h Volume:

378.60K

Relative Volume:

0.42

Market Cap:

$1.84B

Revenue:

$868.45M

Net Income/Loss:

$158.69M

P/E Ratio:

11.75

EPS:

2.7087

Net Cash Flow:

$328.64M

1W Performance:

+3.34%

1M Performance:

+13.84%

6M Performance:

+11.41%

1Y Performance:

+6.60%

1-Day Range:

$31.02

$31.86

1-Week Range:

$30.45

$31.86

52-Week Range:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

293

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	31.83	1.84B	868.45M	158.69M	328.64M	2.7087
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

May 03, 2026

CX Institutional Increases Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

May 03, 2026

Capital Management Corp VA Sells 41,191 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

May 03, 2026

May 02, 2026

HRMY stock on track for best intraday gains in 18 months — what did Mizuho analysts say? - MSN

May 02, 2026

Price-Driven Insight from (HRMY) for Rule-Based Strategy - Stock Traders Daily

May 02, 2026

May 01, 2026

Earnings Preview: HRMY to Report Financial Results Pre-market on May 07 - Moomoo

May 01, 2026

Apr 30, 2026

M3Sixty Small Cap Growth Fund's Harmony Biosciences Holdings Inc(HRMY) Holding History - GuruFocus

Apr 30, 2026

Harmony Bio spikes after new Wakix patent litigation - MSN

Apr 30, 2026

Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

A Look At Harmony Biosciences (HRMY) Valuation After CFO Appointment And Reaffirmed 2026 Revenue Outlook - Sahm

Apr 29, 2026

Apr 27, 2026

Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance

Apr 24, 2026

H.C. Wainwright reiterates Harmony Biosciences stock rating on IP litigation outlook By Investing.com - Investing.com South Africa

Apr 24, 2026

H.C. Wainwright reiterates Harmony Biosciences stock rating on IP litigation outlook - Investing.com Australia

Apr 24, 2026

Research Analysts Issue Forecasts for HRMY Q1 Earnings - MarketBeat

Apr 24, 2026

Why Harmony Biosciences (HRMY) Reaffirmed 2026 Revenue Guidance and Hired a Markets-Focused CFO - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Harmony Biosciences (HRMY) Attracts Buy Rating Amid IP Litigatio - GuruFocus

Apr 23, 2026

Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy - MSN

Apr 23, 2026